Evidence map›Paper›PMID 27799873›Full record

ReviewImmune network2016

Development of Auto Antigen-specific Regulatory T Cells for Diabetes Immunotherapy.

Jianxun Song

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immune network, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives.Clinical medicine insights. Endocrinology and diabetes · 2019
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jianxun SongDepartment of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Pennsylvania State University · US

Funding

Stem cell-derived regulatory T cells for therapeutic use in arthritisR01AI121180 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI SONG, JIANXUN JIM · 2016 to 2020
$1.9M
Directed differentiation of HBV-specific CTL from iPSC for cell-based therapiesR21AI109239 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SONG, JIANXUN JIM · 2014 to 2015
$441k
Role of stem cell-derived T lymphocytes in chronic HBV infectionR21AI128325 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI SONG, JIANXUN JIM · 2017 to 2018
$419k
Impact of Highly Active T Lymphocytes from Induced Pluripotent Stem CellsK18CA151798 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SONG, JIANXUN JIM · 2011 to 2012
$234k
NCI NIH HHS K18 CA151798NIAID NIH HHS R01 AI121180NIAID NIH HHS R21 AI109239NIAID NIH HHS R21 AI128325
6 · The paper itself

Abstract

CD4

Indexed as

DiabetesImmunotherapyRegulatory T cellsStem cellsT cellsTolerance

Identifiers

PMID27799873
PMCPMC5086452
OpenAlexW2540347122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.